Flex Pharma, Inc. (FLKS) Scheduled to Post Earnings on Tuesday
Flex Pharma, Inc. (NASDAQ:FLKS) is scheduled to be posting its quarterly earnings results before the market opens on Tuesday, October 31st. Analysts expect Flex Pharma to post earnings of ($0.60) per share for the quarter.
Flex Pharma (NASDAQ:FLKS) last posted its earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.51) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.63) by $0.12. The firm had revenue of $0.34 million for the quarter, compared to the consensus estimate of $0.46 million. Flex Pharma had a negative net margin of 2,410.97% and a negative return on equity of 64.15%. On average, analysts expect Flex Pharma to post $-2.4 EPS for the current fiscal year and $-2.13 EPS for the next fiscal year.
Flex Pharma, Inc. (NASDAQ FLKS) opened at 3.015 on Tuesday. Flex Pharma, Inc. has a 52-week low of $2.90 and a 52-week high of $7.55. The stock’s market capitalization is $52.11 million. The company has a 50 day moving average of $3.40 and a 200-day moving average of $3.40.
A number of analysts have weighed in on the stock. Zacks Investment Research raised shares of Flex Pharma from a “hold” rating to a “buy” rating and set a $3.75 target price on the stock in a report on Tuesday, October 3rd. Cantor Fitzgerald reissued a “hold” rating and set a $10.00 target price on shares of Flex Pharma in a report on Monday, September 25th. Finally, Roth Capital assumed coverage on shares of Flex Pharma in a report on Thursday, September 7th. They set a “buy” rating and a $14.00 target price on the stock. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $9.55.
Flex Pharma Company Profile
Flex Pharma, Inc is a biotechnology company. The Company develops treatments for nocturnal leg cramps, muscle cramps and spasms associated with severe neuromuscular conditions, and exercise associated muscle cramps (EAMCs). The Company’s product candidates activate certain receptors in primary sensory neurons, which then act through neuronal circuits to reduce the repetitive firing, or hyperexcitability, of alpha-motor neurons in the spinal cord, thereby preventing or reducing the frequency and intensity of muscle cramps and spasms.
Receive News & Ratings for Flex Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flex Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.